Professur für Molekulare Mechanismen der Organfibrose

Reallocation / Closing: 30.09.2022


Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS) (2017) Herrick AL, Pan X, Peytrignet S, Lunt M, Hesselstrand R, Mouthon L, Silman A, et al. Journal article Nintedanib macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis (2017) Huang J, Maier C, Zhang Y, Soare A, Dees C, Beyer C, Harre U, et al. Journal article Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (2017) Peytrignet S, Denton CP, Lunt M, Hesselstrand R, Mouthon L, Silman A, Pan X, et al. Journal article Elevated serum levels of sonic hedgehog are associated with fibrotic and vascular manifestations in systemic sclerosis (2017) Beyer C, Huscher D, Ramming A, Bergmann C, Avouac J, Guiducci S, Meier F, et al. Journal article The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis (2017) Bergmann C, Brandt A, Merlevede B, Hallenberger L, Dees C, Wohlfahrt T, Pötter S, et al. Journal article Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study (2017) Hsu VM, Denton CP, Domsic RT, Furst DE, Rischmueller M, Stanislav M, Steen VD, et al. Journal article Type 2 Innate Lymphoid Cells - Cellular Source of Profibrotic Mediators Rapidly and Persistently Recruited in Experimental Fibrosis and Systemic Sclerosis (2016) Weber S, Wohlfahrt T, Rauber S, Luber M, Englbrecht M, Dees C, Beyer C, et al. Conference contribution THE INVOLVEMENT OF THE LONG NONCODING H19X IN TGF beta SIGNALING AND ITS PROFIBROTIC EFFECTS IN SYSTEMIC SCLEROSIS AND OTHER FIBROTIC DISEASES (2016) Pachera E, Assassi S, Salazar G, Frank-Bertoncelj M, Dobrota R, Brock M, Kurreeman F, et al. Conference contribution THE SEROTONIN RECEPTOR 2 INHIBITOR TERGURIDE HAS BENEFICIAL EFFECTS ON SKIN FIBROSIS: RESULTS FROM A PHASE 2 PROOF OF CONCEPT STUDY (2016) Distler O, Maurer B, Vettori S, Blumhardt S, Frey D, Distler A, Beyer C, Distler J Conference contribution Variable effects of different serotonin receptor subtype antagonists on the development of transplant vasculopathy in murine aortic allografts (2016) Heim C, Gocht A, Distler J, Spriewald B, Ramsperger-Gleixner M, Weyand M, Ensminger SM Conference contribution